nodes	percent_of_prediction	percent_of_DWPC	metapath
Pasireotide—SSTR2—GPCRs, Other—ADGRV1—peripheral nervous system neoplasm	0.0422	0.115	CbGpPWpGaD
Pasireotide—SSTR5—brainstem—peripheral nervous system neoplasm	0.0207	0.199	CbGeAlD
Pasireotide—SSTR3—brainstem—peripheral nervous system neoplasm	0.0199	0.191	CbGeAlD
Pasireotide—SSTR1—SIDS Susceptibility Pathways—PHOX2B—peripheral nervous system neoplasm	0.0193	0.0526	CbGpPWpGaD
Pasireotide—SSTR2—SIDS Susceptibility Pathways—PHOX2B—peripheral nervous system neoplasm	0.0158	0.043	CbGpPWpGaD
Pasireotide—SSTR1—brainstem—peripheral nervous system neoplasm	0.0157	0.151	CbGeAlD
Pasireotide—SSTR2—brainstem—peripheral nervous system neoplasm	0.0134	0.128	CbGeAlD
Pasireotide—SSTR5—cerebellum—peripheral nervous system neoplasm	0.0102	0.0983	CbGeAlD
Pasireotide—SSTR3—cerebellum—peripheral nervous system neoplasm	0.0098	0.0942	CbGeAlD
Pasireotide—SSTR3—Peptide ligand-binding receptors—NTS—peripheral nervous system neoplasm	0.0094	0.0257	CbGpPWpGaD
Pasireotide—SSTR1—Peptide ligand-binding receptors—NTS—peripheral nervous system neoplasm	0.00901	0.0246	CbGpPWpGaD
Pasireotide—SSTR5—Peptide ligand-binding receptors—NTS—peripheral nervous system neoplasm	0.00799	0.0218	CbGpPWpGaD
Pasireotide—SSTR1—cerebellum—peripheral nervous system neoplasm	0.00775	0.0745	CbGeAlD
Pasireotide—SSTR2—Peptide ligand-binding receptors—NTS—peripheral nervous system neoplasm	0.00738	0.0201	CbGpPWpGaD
Pasireotide—SSTR2—cerebellum—peripheral nervous system neoplasm	0.00659	0.0633	CbGeAlD
Pasireotide—SSTR3—Class A/1 (Rhodopsin-like receptors)—NTS—peripheral nervous system neoplasm	0.0063	0.0172	CbGpPWpGaD
Pasireotide—SSTR1—Class A/1 (Rhodopsin-like receptors)—NTS—peripheral nervous system neoplasm	0.00604	0.0165	CbGpPWpGaD
Pasireotide—SSTR1—SIDS Susceptibility Pathways—NTRK2—peripheral nervous system neoplasm	0.00554	0.0151	CbGpPWpGaD
Pasireotide—SSTR5—Class A/1 (Rhodopsin-like receptors)—NTS—peripheral nervous system neoplasm	0.00536	0.0146	CbGpPWpGaD
Pasireotide—SSTR1—SIDS Susceptibility Pathways—TH—peripheral nervous system neoplasm	0.00508	0.0139	CbGpPWpGaD
Pasireotide—SSTR2—Class A/1 (Rhodopsin-like receptors)—NTS—peripheral nervous system neoplasm	0.00495	0.0135	CbGpPWpGaD
Pasireotide—SSTR3—GPCR ligand binding—NTS—peripheral nervous system neoplasm	0.0048	0.0131	CbGpPWpGaD
Pasireotide—SSTR3—GPCR ligand binding—CD55—peripheral nervous system neoplasm	0.0046	0.0126	CbGpPWpGaD
Pasireotide—SSTR1—GPCR ligand binding—NTS—peripheral nervous system neoplasm	0.0046	0.0126	CbGpPWpGaD
Pasireotide—SSTR2—SIDS Susceptibility Pathways—NTRK2—peripheral nervous system neoplasm	0.00454	0.0124	CbGpPWpGaD
Pasireotide—SSTR1—GPCR ligand binding—CD55—peripheral nervous system neoplasm	0.00441	0.012	CbGpPWpGaD
Pasireotide—SSTR3—Peptide ligand-binding receptors—KNG1—peripheral nervous system neoplasm	0.00422	0.0115	CbGpPWpGaD
Pasireotide—Nasopharyngitis—Isotretinoin—peripheral nervous system neoplasm	0.00417	0.00787	CcSEcCtD
Pasireotide—SSTR2—SIDS Susceptibility Pathways—TH—peripheral nervous system neoplasm	0.00416	0.0113	CbGpPWpGaD
Pasireotide—Alanine aminotransferase increased—Topotecan—peripheral nervous system neoplasm	0.00414	0.00782	CcSEcCtD
Pasireotide—SSTR1—SIDS Susceptibility Pathways—BDNF—peripheral nervous system neoplasm	0.00414	0.0113	CbGpPWpGaD
Pasireotide—SSTR5—GPCR ligand binding—NTS—peripheral nervous system neoplasm	0.00408	0.0111	CbGpPWpGaD
Pasireotide—Diabetes mellitus—Alitretinoin—peripheral nervous system neoplasm	0.00406	0.00767	CcSEcCtD
Pasireotide—Abdominal distension—Tretinoin—peripheral nervous system neoplasm	0.00406	0.00766	CcSEcCtD
Pasireotide—Abdominal distension—Isotretinoin—peripheral nervous system neoplasm	0.00406	0.00766	CcSEcCtD
Pasireotide—SSTR1—Peptide ligand-binding receptors—KNG1—peripheral nervous system neoplasm	0.00405	0.0111	CbGpPWpGaD
Pasireotide—SSTR5—GPCR ligand binding—CD55—peripheral nervous system neoplasm	0.00391	0.0107	CbGpPWpGaD
Pasireotide—SSTR2—GPCR ligand binding—NTS—peripheral nervous system neoplasm	0.00377	0.0103	CbGpPWpGaD
Pasireotide—SSTR2—GPCR ligand binding—CD55—peripheral nervous system neoplasm	0.00361	0.00986	CbGpPWpGaD
Pasireotide—SSTR5—Peptide ligand-binding receptors—KNG1—peripheral nervous system neoplasm	0.00359	0.0098	CbGpPWpGaD
Pasireotide—SSTR3—G alpha (i) signalling events—KNG1—peripheral nervous system neoplasm	0.00356	0.00973	CbGpPWpGaD
Pasireotide—Pain in extremity—Alitretinoin—peripheral nervous system neoplasm	0.00353	0.00667	CcSEcCtD
Pasireotide—Aspartate aminotransferase increased—Dactinomycin—peripheral nervous system neoplasm	0.00343	0.00648	CcSEcCtD
Pasireotide—SSTR1—G alpha (i) signalling events—KNG1—peripheral nervous system neoplasm	0.00342	0.00933	CbGpPWpGaD
Pasireotide—Pain in extremity—Vincristine—peripheral nervous system neoplasm	0.0034	0.00643	CcSEcCtD
Pasireotide—SSTR2—SIDS Susceptibility Pathways—BDNF—peripheral nervous system neoplasm	0.00339	0.00924	CbGpPWpGaD
Pasireotide—SSTR2—Peptide ligand-binding receptors—KNG1—peripheral nervous system neoplasm	0.00331	0.00905	CbGpPWpGaD
Pasireotide—Dry skin—Alitretinoin—peripheral nervous system neoplasm	0.00324	0.00611	CcSEcCtD
Pasireotide—Oedema peripheral—Isotretinoin—peripheral nervous system neoplasm	0.00318	0.006	CcSEcCtD
Pasireotide—Oedema peripheral—Tretinoin—peripheral nervous system neoplasm	0.00318	0.006	CcSEcCtD
Pasireotide—Nasopharyngitis—Alitretinoin—peripheral nervous system neoplasm	0.00316	0.00596	CcSEcCtD
Pasireotide—SSTR3—G alpha (i) signalling events—GNAS—peripheral nervous system neoplasm	0.00312	0.00851	CbGpPWpGaD
Pasireotide—Abdominal distension—Alitretinoin—peripheral nervous system neoplasm	0.00307	0.0058	CcSEcCtD
Pasireotide—Aspartate aminotransferase increased—Vincristine—peripheral nervous system neoplasm	0.00307	0.00579	CcSEcCtD
Pasireotide—SSTR5—G alpha (i) signalling events—KNG1—peripheral nervous system neoplasm	0.00303	0.00827	CbGpPWpGaD
Pasireotide—SSTR1—G alpha (i) signalling events—GNAS—peripheral nervous system neoplasm	0.00299	0.00816	CbGpPWpGaD
Pasireotide—Alopecia—Topotecan—peripheral nervous system neoplasm	0.00287	0.00542	CcSEcCtD
Pasireotide—Alopecia—Isotretinoin—peripheral nervous system neoplasm	0.00285	0.00538	CcSEcCtD
Pasireotide—Alopecia—Tretinoin—peripheral nervous system neoplasm	0.00285	0.00538	CcSEcCtD
Pasireotide—SSTR3—Class A/1 (Rhodopsin-like receptors)—KNG1—peripheral nervous system neoplasm	0.00283	0.00773	CbGpPWpGaD
Pasireotide—Alopecia—Melphalan—peripheral nervous system neoplasm	0.00281	0.00531	CcSEcCtD
Pasireotide—SSTR2—G alpha (i) signalling events—KNG1—peripheral nervous system neoplasm	0.0028	0.00763	CbGpPWpGaD
Pasireotide—Hypokalaemia—Cisplatin—peripheral nervous system neoplasm	0.00274	0.00517	CcSEcCtD
Pasireotide—Back pain—Topotecan—peripheral nervous system neoplasm	0.00274	0.00517	CcSEcCtD
Pasireotide—SSTR1—Class A/1 (Rhodopsin-like receptors)—KNG1—peripheral nervous system neoplasm	0.00272	0.00742	CbGpPWpGaD
Pasireotide—Back pain—Isotretinoin—peripheral nervous system neoplasm	0.00272	0.00513	CcSEcCtD
Pasireotide—Back pain—Tretinoin—peripheral nervous system neoplasm	0.00272	0.00513	CcSEcCtD
Pasireotide—SSTR3—GPCR downstream signaling—NTS—peripheral nervous system neoplasm	0.00271	0.00741	CbGpPWpGaD
Pasireotide—Aspartate aminotransferase increased—Cisplatin—peripheral nervous system neoplasm	0.00271	0.00512	CcSEcCtD
Pasireotide—Nasopharyngitis—Cisplatin—peripheral nervous system neoplasm	0.00269	0.00508	CcSEcCtD
Pasireotide—SSTR5—G alpha (i) signalling events—GNAS—peripheral nervous system neoplasm	0.00265	0.00723	CbGpPWpGaD
Pasireotide—Anaemia—Topotecan—peripheral nervous system neoplasm	0.00262	0.00494	CcSEcCtD
Pasireotide—SSTR1—GPCR downstream signaling—NTS—peripheral nervous system neoplasm	0.0026	0.0071	CbGpPWpGaD
Pasireotide—Anaemia—Isotretinoin—peripheral nervous system neoplasm	0.00259	0.0049	CcSEcCtD
Pasireotide—Anaemia—Tretinoin—peripheral nervous system neoplasm	0.00259	0.0049	CcSEcCtD
Pasireotide—Anaemia—Melphalan—peripheral nervous system neoplasm	0.00256	0.00483	CcSEcCtD
Pasireotide—SSTR3—Signaling by GPCR—NTS—peripheral nervous system neoplasm	0.00246	0.00673	CbGpPWpGaD
Pasireotide—SSTR2—G alpha (i) signalling events—GNAS—peripheral nervous system neoplasm	0.00244	0.00668	CbGpPWpGaD
Pasireotide—Alanine aminotransferase increased—Etoposide—peripheral nervous system neoplasm	0.00243	0.00459	CcSEcCtD
Pasireotide—Hypertension—Isotretinoin—peripheral nervous system neoplasm	0.00242	0.00457	CcSEcCtD
Pasireotide—Hypertension—Tretinoin—peripheral nervous system neoplasm	0.00242	0.00457	CcSEcCtD
Pasireotide—Myalgia—Topotecan—peripheral nervous system neoplasm	0.00241	0.00455	CcSEcCtD
Pasireotide—Arthralgia—Topotecan—peripheral nervous system neoplasm	0.00241	0.00455	CcSEcCtD
Pasireotide—SSTR5—Class A/1 (Rhodopsin-like receptors)—KNG1—peripheral nervous system neoplasm	0.00241	0.00658	CbGpPWpGaD
Pasireotide—Oedema peripheral—Alitretinoin—peripheral nervous system neoplasm	0.00241	0.00454	CcSEcCtD
Pasireotide—Arthralgia—Tretinoin—peripheral nervous system neoplasm	0.00239	0.00451	CcSEcCtD
Pasireotide—Arthralgia—Isotretinoin—peripheral nervous system neoplasm	0.00239	0.00451	CcSEcCtD
Pasireotide—Myalgia—Tretinoin—peripheral nervous system neoplasm	0.00239	0.00451	CcSEcCtD
Pasireotide—Myalgia—Isotretinoin—peripheral nervous system neoplasm	0.00239	0.00451	CcSEcCtD
Pasireotide—Anxiety—Tretinoin—peripheral nervous system neoplasm	0.00238	0.0045	CcSEcCtD
Pasireotide—Anxiety—Isotretinoin—peripheral nervous system neoplasm	0.00238	0.0045	CcSEcCtD
Pasireotide—SSTR3—Signaling by GPCR—CD55—peripheral nervous system neoplasm	0.00236	0.00645	CbGpPWpGaD
Pasireotide—SSTR1—Signaling by GPCR—NTS—peripheral nervous system neoplasm	0.00236	0.00645	CbGpPWpGaD
Pasireotide—Myalgia—Melphalan—peripheral nervous system neoplasm	0.00236	0.00445	CcSEcCtD
Pasireotide—Alopecia—Dactinomycin—peripheral nervous system neoplasm	0.00233	0.0044	CcSEcCtD
Pasireotide—SSTR5—GPCR downstream signaling—NTS—peripheral nervous system neoplasm	0.00231	0.0063	CbGpPWpGaD
Pasireotide—SSTR1—Signaling by GPCR—CD55—peripheral nervous system neoplasm	0.00226	0.00618	CbGpPWpGaD
Pasireotide—SSTR2—Class A/1 (Rhodopsin-like receptors)—KNG1—peripheral nervous system neoplasm	0.00222	0.00607	CbGpPWpGaD
Pasireotide—Alopecia—Alitretinoin—peripheral nervous system neoplasm	0.00216	0.00408	CcSEcCtD
Pasireotide—SSTR3—GPCR ligand binding—KNG1—peripheral nervous system neoplasm	0.00216	0.00589	CbGpPWpGaD
Pasireotide—Hypotension—Tretinoin—peripheral nervous system neoplasm	0.00214	0.00404	CcSEcCtD
Pasireotide—Hypotension—Isotretinoin—peripheral nervous system neoplasm	0.00214	0.00404	CcSEcCtD
Pasireotide—SSTR2—GPCR downstream signaling—NTS—peripheral nervous system neoplasm	0.00213	0.00581	CbGpPWpGaD
Pasireotide—Anaemia—Dactinomycin—peripheral nervous system neoplasm	0.00212	0.004	CcSEcCtD
Pasireotide—Injection site reaction—Epirubicin—peripheral nervous system neoplasm	0.00212	0.004	CcSEcCtD
Pasireotide—Hypotension—Melphalan—peripheral nervous system neoplasm	0.00211	0.00399	CcSEcCtD
Pasireotide—Musculoskeletal discomfort—Topotecan—peripheral nervous system neoplasm	0.0021	0.00397	CcSEcCtD
Pasireotide—SSTR5—Signaling by GPCR—NTS—peripheral nervous system neoplasm	0.00209	0.00572	CbGpPWpGaD
Pasireotide—Musculoskeletal discomfort—Tretinoin—peripheral nervous system neoplasm	0.00209	0.00394	CcSEcCtD
Pasireotide—Musculoskeletal discomfort—Isotretinoin—peripheral nervous system neoplasm	0.00209	0.00394	CcSEcCtD
Pasireotide—Alopecia—Vincristine—peripheral nervous system neoplasm	0.00208	0.00393	CcSEcCtD
Pasireotide—Insomnia—Tretinoin—peripheral nervous system neoplasm	0.00207	0.00391	CcSEcCtD
Pasireotide—Insomnia—Isotretinoin—peripheral nervous system neoplasm	0.00207	0.00391	CcSEcCtD
Pasireotide—SSTR1—GPCR ligand binding—KNG1—peripheral nervous system neoplasm	0.00207	0.00565	CbGpPWpGaD
Pasireotide—SSTR1—SIDS Susceptibility Pathways—CASP3—peripheral nervous system neoplasm	0.00207	0.00564	CbGpPWpGaD
Pasireotide—Musculoskeletal discomfort—Melphalan—peripheral nervous system neoplasm	0.00206	0.00389	CcSEcCtD
Pasireotide—Back pain—Alitretinoin—peripheral nervous system neoplasm	0.00206	0.00388	CcSEcCtD
Pasireotide—SSTR3—GPCR downstream signaling—VIP—peripheral nervous system neoplasm	0.00206	0.00561	CbGpPWpGaD
Pasireotide—SSTR5—Signaling by GPCR—CD55—peripheral nervous system neoplasm	0.00201	0.00548	CbGpPWpGaD
Pasireotide—Decreased appetite—Topotecan—peripheral nervous system neoplasm	0.00201	0.00379	CcSEcCtD
Pasireotide—Decreased appetite—Tretinoin—peripheral nervous system neoplasm	0.00199	0.00376	CcSEcCtD
Pasireotide—Decreased appetite—Isotretinoin—peripheral nervous system neoplasm	0.00199	0.00376	CcSEcCtD
Pasireotide—Fatigue—Topotecan—peripheral nervous system neoplasm	0.00199	0.00376	CcSEcCtD
Pasireotide—Back pain—Vincristine—peripheral nervous system neoplasm	0.00198	0.00374	CcSEcCtD
Pasireotide—Fatigue—Isotretinoin—peripheral nervous system neoplasm	0.00198	0.00373	CcSEcCtD
Pasireotide—Fatigue—Tretinoin—peripheral nervous system neoplasm	0.00198	0.00373	CcSEcCtD
Pasireotide—Constipation—Topotecan—peripheral nervous system neoplasm	0.00197	0.00373	CcSEcCtD
Pasireotide—SSTR1—GPCR downstream signaling—VIP—peripheral nervous system neoplasm	0.00197	0.00538	CbGpPWpGaD
Pasireotide—Anaemia—Alitretinoin—peripheral nervous system neoplasm	0.00197	0.00371	CcSEcCtD
Pasireotide—Decreased appetite—Melphalan—peripheral nervous system neoplasm	0.00197	0.00371	CcSEcCtD
Pasireotide—Constipation—Isotretinoin—peripheral nervous system neoplasm	0.00196	0.0037	CcSEcCtD
Pasireotide—Constipation—Tretinoin—peripheral nervous system neoplasm	0.00196	0.0037	CcSEcCtD
Pasireotide—Injection site reaction—Doxorubicin—peripheral nervous system neoplasm	0.00196	0.0037	CcSEcCtD
Pasireotide—Myalgia—Dactinomycin—peripheral nervous system neoplasm	0.00195	0.00369	CcSEcCtD
Pasireotide—Fatigue—Melphalan—peripheral nervous system neoplasm	0.00195	0.00368	CcSEcCtD
Pasireotide—SSTR2—Signaling by GPCR—NTS—peripheral nervous system neoplasm	0.00193	0.00528	CbGpPWpGaD
Pasireotide—Anaemia—Vincristine—peripheral nervous system neoplasm	0.00189	0.00358	CcSEcCtD
Pasireotide—Gastrointestinal pain—Topotecan—peripheral nervous system neoplasm	0.00189	0.00356	CcSEcCtD
Pasireotide—SSTR3—GPCR ligand binding—GNAS—peripheral nervous system neoplasm	0.00189	0.00515	CbGpPWpGaD
Pasireotide—Gastrointestinal pain—Tretinoin—peripheral nervous system neoplasm	0.00187	0.00354	CcSEcCtD
Pasireotide—Gastrointestinal pain—Isotretinoin—peripheral nervous system neoplasm	0.00187	0.00354	CcSEcCtD
Pasireotide—SSTR3—Signaling by GPCR—VIP—peripheral nervous system neoplasm	0.00187	0.0051	CbGpPWpGaD
Pasireotide—SSTR2—Signaling by GPCR—CD55—peripheral nervous system neoplasm	0.00185	0.00506	CbGpPWpGaD
Pasireotide—Vertigo—Vincristine—peripheral nervous system neoplasm	0.00184	0.00348	CcSEcCtD
Pasireotide—Alopecia—Cisplatin—peripheral nervous system neoplasm	0.00184	0.00347	CcSEcCtD
Pasireotide—Hypertension—Alitretinoin—peripheral nervous system neoplasm	0.00184	0.00347	CcSEcCtD
Pasireotide—SSTR5—GPCR ligand binding—KNG1—peripheral nervous system neoplasm	0.00183	0.00501	CbGpPWpGaD
Pasireotide—Abdominal pain—Topotecan—peripheral nervous system neoplasm	0.00183	0.00345	CcSEcCtD
Pasireotide—Arthralgia—Alitretinoin—peripheral nervous system neoplasm	0.00181	0.00342	CcSEcCtD
Pasireotide—Myalgia—Alitretinoin—peripheral nervous system neoplasm	0.00181	0.00342	CcSEcCtD
Pasireotide—Abdominal pain—Isotretinoin—peripheral nervous system neoplasm	0.00181	0.00342	CcSEcCtD
Pasireotide—Abdominal pain—Tretinoin—peripheral nervous system neoplasm	0.00181	0.00342	CcSEcCtD
Pasireotide—SSTR1—GPCR ligand binding—GNAS—peripheral nervous system neoplasm	0.00181	0.00494	CbGpPWpGaD
Pasireotide—Anxiety—Alitretinoin—peripheral nervous system neoplasm	0.0018	0.00341	CcSEcCtD
Pasireotide—SSTR1—Signaling by GPCR—VIP—peripheral nervous system neoplasm	0.00179	0.00489	CbGpPWpGaD
Pasireotide—Diabetes mellitus—Epirubicin—peripheral nervous system neoplasm	0.00178	0.00335	CcSEcCtD
Pasireotide—Hypertension—Vincristine—peripheral nervous system neoplasm	0.00177	0.00334	CcSEcCtD
Pasireotide—SSTR5—GPCR downstream signaling—VIP—peripheral nervous system neoplasm	0.00175	0.00477	CbGpPWpGaD
Pasireotide—Myalgia—Vincristine—peripheral nervous system neoplasm	0.00175	0.00329	CcSEcCtD
Pasireotide—SSTR3—Signaling by GPCR—PPP3R1—peripheral nervous system neoplasm	0.00172	0.0047	CbGpPWpGaD
Pasireotide—Musculoskeletal discomfort—Dactinomycin—peripheral nervous system neoplasm	0.00171	0.00322	CcSEcCtD
Pasireotide—SSTR2—GPCR ligand binding—KNG1—peripheral nervous system neoplasm	0.00169	0.00462	CbGpPWpGaD
Pasireotide—SSTR2—SIDS Susceptibility Pathways—CASP3—peripheral nervous system neoplasm	0.00169	0.00462	CbGpPWpGaD
Pasireotide—Alopecia—Etoposide—peripheral nervous system neoplasm	0.00169	0.00318	CcSEcCtD
Pasireotide—Anaemia—Cisplatin—peripheral nervous system neoplasm	0.00168	0.00316	CcSEcCtD
Pasireotide—Asthenia—Topotecan—peripheral nervous system neoplasm	0.00166	0.00313	CcSEcCtD
Pasireotide—SSTR1—Signaling by GPCR—PPP3R1—peripheral nervous system neoplasm	0.00165	0.00451	CbGpPWpGaD
Pasireotide—Diabetes mellitus—Doxorubicin—peripheral nervous system neoplasm	0.00164	0.0031	CcSEcCtD
Pasireotide—Asthenia—Tretinoin—peripheral nervous system neoplasm	0.00164	0.0031	CcSEcCtD
Pasireotide—Asthenia—Isotretinoin—peripheral nervous system neoplasm	0.00164	0.0031	CcSEcCtD
Pasireotide—Pruritus—Topotecan—peripheral nervous system neoplasm	0.00163	0.00308	CcSEcCtD
Pasireotide—Decreased appetite—Dactinomycin—peripheral nervous system neoplasm	0.00163	0.00307	CcSEcCtD
Pasireotide—Asthenia—Melphalan—peripheral nervous system neoplasm	0.00162	0.00306	CcSEcCtD
Pasireotide—Hypotension—Alitretinoin—peripheral nervous system neoplasm	0.00162	0.00306	CcSEcCtD
Pasireotide—Pruritus—Tretinoin—peripheral nervous system neoplasm	0.00162	0.00306	CcSEcCtD
Pasireotide—Pruritus—Isotretinoin—peripheral nervous system neoplasm	0.00162	0.00306	CcSEcCtD
Pasireotide—Fatigue—Dactinomycin—peripheral nervous system neoplasm	0.00161	0.00305	CcSEcCtD
Pasireotide—SSTR2—GPCR downstream signaling—VIP—peripheral nervous system neoplasm	0.00161	0.00441	CbGpPWpGaD
Pasireotide—Back pain—Etoposide—peripheral nervous system neoplasm	0.00161	0.00303	CcSEcCtD
Pasireotide—SSTR5—GPCR ligand binding—GNAS—peripheral nervous system neoplasm	0.0016	0.00438	CbGpPWpGaD
Pasireotide—Pruritus—Melphalan—peripheral nervous system neoplasm	0.0016	0.00302	CcSEcCtD
Pasireotide—SSTR5—Signaling by GPCR—VIP—peripheral nervous system neoplasm	0.00159	0.00433	CbGpPWpGaD
Pasireotide—Hypoglycaemia—Epirubicin—peripheral nervous system neoplasm	0.00158	0.00299	CcSEcCtD
Pasireotide—Musculoskeletal discomfort—Alitretinoin—peripheral nervous system neoplasm	0.00158	0.00299	CcSEcCtD
Pasireotide—Diarrhoea—Topotecan—peripheral nervous system neoplasm	0.00158	0.00298	CcSEcCtD
Pasireotide—Insomnia—Alitretinoin—peripheral nervous system neoplasm	0.00157	0.00296	CcSEcCtD
Pasireotide—Diarrhoea—Tretinoin—peripheral nervous system neoplasm	0.00157	0.00296	CcSEcCtD
Pasireotide—Diarrhoea—Isotretinoin—peripheral nervous system neoplasm	0.00157	0.00296	CcSEcCtD
Pasireotide—Hypotension—Vincristine—peripheral nervous system neoplasm	0.00156	0.00295	CcSEcCtD
Pasireotide—Diarrhoea—Melphalan—peripheral nervous system neoplasm	0.00155	0.00292	CcSEcCtD
Pasireotide—Pain in extremity—Epirubicin—peripheral nervous system neoplasm	0.00155	0.00292	CcSEcCtD
Pasireotide—Myalgia—Cisplatin—peripheral nervous system neoplasm	0.00154	0.00291	CcSEcCtD
Pasireotide—Anxiety—Cisplatin—peripheral nervous system neoplasm	0.00154	0.0029	CcSEcCtD
Pasireotide—Anaemia—Etoposide—peripheral nervous system neoplasm	0.00153	0.0029	CcSEcCtD
Pasireotide—Gastrointestinal pain—Dactinomycin—peripheral nervous system neoplasm	0.00153	0.00289	CcSEcCtD
Pasireotide—Dizziness—Topotecan—peripheral nervous system neoplasm	0.00153	0.00288	CcSEcCtD
Pasireotide—Musculoskeletal discomfort—Vincristine—peripheral nervous system neoplasm	0.00152	0.00288	CcSEcCtD
Pasireotide—Dizziness—Isotretinoin—peripheral nervous system neoplasm	0.00151	0.00286	CcSEcCtD
Pasireotide—Dizziness—Tretinoin—peripheral nervous system neoplasm	0.00151	0.00286	CcSEcCtD
Pasireotide—Insomnia—Vincristine—peripheral nervous system neoplasm	0.00151	0.00286	CcSEcCtD
Pasireotide—Decreased appetite—Alitretinoin—peripheral nervous system neoplasm	0.00151	0.00285	CcSEcCtD
Pasireotide—Fatigue—Alitretinoin—peripheral nervous system neoplasm	0.0015	0.00283	CcSEcCtD
Pasireotide—Vertigo—Etoposide—peripheral nervous system neoplasm	0.00149	0.00282	CcSEcCtD
Pasireotide—Constipation—Alitretinoin—peripheral nervous system neoplasm	0.00148	0.0028	CcSEcCtD
Pasireotide—SSTR2—GPCR ligand binding—GNAS—peripheral nervous system neoplasm	0.00148	0.00404	CbGpPWpGaD
Pasireotide—Abdominal pain—Dactinomycin—peripheral nervous system neoplasm	0.00148	0.00279	CcSEcCtD
Pasireotide—Vomiting—Topotecan—peripheral nervous system neoplasm	0.00147	0.00277	CcSEcCtD
Pasireotide—Hypoglycaemia—Doxorubicin—peripheral nervous system neoplasm	0.00147	0.00277	CcSEcCtD
Pasireotide—SSTR5—Signaling by GPCR—PPP3R1—peripheral nervous system neoplasm	0.00147	0.004	CbGpPWpGaD
Pasireotide—SSTR2—Signaling by GPCR—VIP—peripheral nervous system neoplasm	0.00147	0.004	CbGpPWpGaD
Pasireotide—Vomiting—Tretinoin—peripheral nervous system neoplasm	0.00146	0.00275	CcSEcCtD
Pasireotide—Vomiting—Isotretinoin—peripheral nervous system neoplasm	0.00146	0.00275	CcSEcCtD
Pasireotide—SSTR3—Signaling Pathways—NTS—peripheral nervous system neoplasm	0.00146	0.00397	CbGpPWpGaD
Pasireotide—Decreased appetite—Vincristine—peripheral nervous system neoplasm	0.00145	0.00275	CcSEcCtD
Pasireotide—Headache—Topotecan—peripheral nervous system neoplasm	0.00145	0.00273	CcSEcCtD
Pasireotide—Fatigue—Vincristine—peripheral nervous system neoplasm	0.00144	0.00272	CcSEcCtD
Pasireotide—Vomiting—Melphalan—peripheral nervous system neoplasm	0.00144	0.00271	CcSEcCtD
Pasireotide—Headache—Isotretinoin—peripheral nervous system neoplasm	0.00144	0.00271	CcSEcCtD
Pasireotide—Headache—Tretinoin—peripheral nervous system neoplasm	0.00144	0.00271	CcSEcCtD
Pasireotide—Hypertension—Etoposide—peripheral nervous system neoplasm	0.00143	0.00271	CcSEcCtD
Pasireotide—Constipation—Vincristine—peripheral nervous system neoplasm	0.00143	0.0027	CcSEcCtD
Pasireotide—Pain in extremity—Doxorubicin—peripheral nervous system neoplasm	0.00143	0.0027	CcSEcCtD
Pasireotide—Gastrointestinal pain—Alitretinoin—peripheral nervous system neoplasm	0.00142	0.00268	CcSEcCtD
Pasireotide—Dry skin—Epirubicin—peripheral nervous system neoplasm	0.00142	0.00267	CcSEcCtD
Pasireotide—Abdominal pain upper—Epirubicin—peripheral nervous system neoplasm	0.00141	0.00266	CcSEcCtD
Pasireotide—Hypokalaemia—Epirubicin—peripheral nervous system neoplasm	0.00141	0.00266	CcSEcCtD
Pasireotide—SSTR1—Signaling Pathways—NTS—peripheral nervous system neoplasm	0.0014	0.00381	CbGpPWpGaD
Pasireotide—SSTR3—Signaling Pathways—CD55—peripheral nervous system neoplasm	0.0014	0.00381	CbGpPWpGaD
Pasireotide—Aspartate aminotransferase increased—Epirubicin—peripheral nervous system neoplasm	0.00139	0.00263	CcSEcCtD
Pasireotide—Hypotension—Cisplatin—peripheral nervous system neoplasm	0.00138	0.00261	CcSEcCtD
Pasireotide—Nasopharyngitis—Epirubicin—peripheral nervous system neoplasm	0.00138	0.00261	CcSEcCtD
Pasireotide—Abdominal pain—Alitretinoin—peripheral nervous system neoplasm	0.00137	0.00259	CcSEcCtD
Pasireotide—Nausea—Topotecan—peripheral nervous system neoplasm	0.00137	0.00259	CcSEcCtD
Pasireotide—Gastrointestinal pain—Vincristine—peripheral nervous system neoplasm	0.00137	0.00258	CcSEcCtD
Pasireotide—Alanine aminotransferase increased—Epirubicin—peripheral nervous system neoplasm	0.00136	0.00257	CcSEcCtD
Pasireotide—Nausea—Tretinoin—peripheral nervous system neoplasm	0.00136	0.00257	CcSEcCtD
Pasireotide—Nausea—Isotretinoin—peripheral nervous system neoplasm	0.00136	0.00257	CcSEcCtD
Pasireotide—SSTR2—Signaling by GPCR—PPP3R1—peripheral nervous system neoplasm	0.00135	0.00369	CbGpPWpGaD
Pasireotide—Musculoskeletal discomfort—Cisplatin—peripheral nervous system neoplasm	0.00135	0.00254	CcSEcCtD
Pasireotide—Abdominal distension—Epirubicin—peripheral nervous system neoplasm	0.00134	0.00254	CcSEcCtD
Pasireotide—Asthenia—Dactinomycin—peripheral nervous system neoplasm	0.00134	0.00254	CcSEcCtD
Pasireotide—Nausea—Melphalan—peripheral nervous system neoplasm	0.00134	0.00254	CcSEcCtD
Pasireotide—SSTR1—Signaling Pathways—CD55—peripheral nervous system neoplasm	0.00134	0.00365	CbGpPWpGaD
Pasireotide—Influenza—Epirubicin—peripheral nervous system neoplasm	0.00134	0.00252	CcSEcCtD
Pasireotide—Abdominal pain—Vincristine—peripheral nervous system neoplasm	0.00132	0.0025	CcSEcCtD
Pasireotide—Dry skin—Doxorubicin—peripheral nervous system neoplasm	0.00131	0.00247	CcSEcCtD
Pasireotide—Abdominal pain upper—Doxorubicin—peripheral nervous system neoplasm	0.00131	0.00247	CcSEcCtD
Pasireotide—Hypokalaemia—Doxorubicin—peripheral nervous system neoplasm	0.0013	0.00246	CcSEcCtD
Pasireotide—Aspartate aminotransferase increased—Doxorubicin—peripheral nervous system neoplasm	0.00129	0.00243	CcSEcCtD
Pasireotide—Decreased appetite—Cisplatin—peripheral nervous system neoplasm	0.00129	0.00243	CcSEcCtD
Pasireotide—Diarrhoea—Dactinomycin—peripheral nervous system neoplasm	0.00128	0.00242	CcSEcCtD
Pasireotide—Nasopharyngitis—Doxorubicin—peripheral nervous system neoplasm	0.00128	0.00241	CcSEcCtD
Pasireotide—Hypotension—Etoposide—peripheral nervous system neoplasm	0.00127	0.00239	CcSEcCtD
Pasireotide—Alanine aminotransferase increased—Doxorubicin—peripheral nervous system neoplasm	0.00126	0.00238	CcSEcCtD
Pasireotide—Asthenia—Alitretinoin—peripheral nervous system neoplasm	0.00125	0.00235	CcSEcCtD
Pasireotide—Abdominal distension—Doxorubicin—peripheral nervous system neoplasm	0.00124	0.00235	CcSEcCtD
Pasireotide—SSTR5—Signaling Pathways—NTS—peripheral nervous system neoplasm	0.00124	0.00338	CbGpPWpGaD
Pasireotide—Influenza—Doxorubicin—peripheral nervous system neoplasm	0.00124	0.00233	CcSEcCtD
Pasireotide—Pruritus—Alitretinoin—peripheral nervous system neoplasm	0.00123	0.00232	CcSEcCtD
Pasireotide—SSTR3—GPCR downstream signaling—KNG1—peripheral nervous system neoplasm	0.00122	0.00333	CbGpPWpGaD
Pasireotide—Hyperglycaemia—Epirubicin—peripheral nervous system neoplasm	0.00121	0.00227	CcSEcCtD
Pasireotide—Asthenia—Vincristine—peripheral nervous system neoplasm	0.0012	0.00227	CcSEcCtD
Pasireotide—Vomiting—Dactinomycin—peripheral nervous system neoplasm	0.00119	0.00225	CcSEcCtD
Pasireotide—Diarrhoea—Alitretinoin—peripheral nervous system neoplasm	0.00119	0.00224	CcSEcCtD
Pasireotide—SSTR5—Signaling Pathways—CD55—peripheral nervous system neoplasm	0.00119	0.00324	CbGpPWpGaD
Pasireotide—Decreased appetite—Etoposide—peripheral nervous system neoplasm	0.00118	0.00222	CcSEcCtD
Pasireotide—SSTR1—GPCR downstream signaling—KNG1—peripheral nervous system neoplasm	0.00117	0.00319	CbGpPWpGaD
Pasireotide—Fatigue—Etoposide—peripheral nervous system neoplasm	0.00117	0.00221	CcSEcCtD
Pasireotide—Constipation—Etoposide—peripheral nervous system neoplasm	0.00116	0.00219	CcSEcCtD
Pasireotide—Dizziness—Alitretinoin—peripheral nervous system neoplasm	0.00115	0.00217	CcSEcCtD
Pasireotide—Diarrhoea—Vincristine—peripheral nervous system neoplasm	0.00114	0.00216	CcSEcCtD
Pasireotide—SSTR2—Signaling Pathways—NTS—peripheral nervous system neoplasm	0.00114	0.00312	CbGpPWpGaD
Pasireotide—Hyperglycaemia—Doxorubicin—peripheral nervous system neoplasm	0.00111	0.0021	CcSEcCtD
Pasireotide—Nausea—Dactinomycin—peripheral nervous system neoplasm	0.00111	0.0021	CcSEcCtD
Pasireotide—Gastrointestinal pain—Etoposide—peripheral nervous system neoplasm	0.00111	0.00209	CcSEcCtD
Pasireotide—SSTR3—Signaling by GPCR—KNG1—peripheral nervous system neoplasm	0.00111	0.00302	CbGpPWpGaD
Pasireotide—Dizziness—Vincristine—peripheral nervous system neoplasm	0.00111	0.00209	CcSEcCtD
Pasireotide—Vomiting—Alitretinoin—peripheral nervous system neoplasm	0.0011	0.00208	CcSEcCtD
Pasireotide—SSTR3—Signaling Pathways—VIP—peripheral nervous system neoplasm	0.0011	0.00301	CbGpPWpGaD
Pasireotide—SSTR2—Signaling Pathways—CD55—peripheral nervous system neoplasm	0.00109	0.00299	CbGpPWpGaD
Pasireotide—Headache—Alitretinoin—peripheral nervous system neoplasm	0.00109	0.00205	CcSEcCtD
Pasireotide—Abdominal pain—Etoposide—peripheral nervous system neoplasm	0.00107	0.00202	CcSEcCtD
Pasireotide—SSTR3—GPCR downstream signaling—GNAS—peripheral nervous system neoplasm	0.00107	0.00291	CbGpPWpGaD
Pasireotide—Vomiting—Vincristine—peripheral nervous system neoplasm	0.00106	0.00201	CcSEcCtD
Pasireotide—SSTR1—Signaling by GPCR—KNG1—peripheral nervous system neoplasm	0.00106	0.0029	CbGpPWpGaD
Pasireotide—Asthenia—Cisplatin—peripheral nervous system neoplasm	0.00106	0.002	CcSEcCtD
Pasireotide—SSTR1—Signaling Pathways—VIP—peripheral nervous system neoplasm	0.00106	0.00289	CbGpPWpGaD
Pasireotide—Oedema peripheral—Epirubicin—peripheral nervous system neoplasm	0.00105	0.00199	CcSEcCtD
Pasireotide—Headache—Vincristine—peripheral nervous system neoplasm	0.00105	0.00198	CcSEcCtD
Pasireotide—SSTR5—GPCR downstream signaling—KNG1—peripheral nervous system neoplasm	0.00104	0.00283	CbGpPWpGaD
Pasireotide—Nausea—Alitretinoin—peripheral nervous system neoplasm	0.00103	0.00195	CcSEcCtD
Pasireotide—SSTR1—GPCR downstream signaling—GNAS—peripheral nervous system neoplasm	0.00102	0.00279	CbGpPWpGaD
Pasireotide—SSTR3—Signaling Pathways—PPP3R1—peripheral nervous system neoplasm	0.00102	0.00278	CbGpPWpGaD
Pasireotide—Diarrhoea—Cisplatin—peripheral nervous system neoplasm	0.00101	0.00191	CcSEcCtD
Pasireotide—Nausea—Vincristine—peripheral nervous system neoplasm	0.000994	0.00188	CcSEcCtD
Pasireotide—SSTR1—Signaling Pathways—PPP3R1—peripheral nervous system neoplasm	0.000976	0.00266	CbGpPWpGaD
Pasireotide—Oedema peripheral—Doxorubicin—peripheral nervous system neoplasm	0.000975	0.00184	CcSEcCtD
Pasireotide—Asthenia—Etoposide—peripheral nervous system neoplasm	0.000972	0.00184	CcSEcCtD
Pasireotide—SSTR3—Signaling by GPCR—GNAS—peripheral nervous system neoplasm	0.000968	0.00264	CbGpPWpGaD
Pasireotide—Pruritus—Etoposide—peripheral nervous system neoplasm	0.000959	0.00181	CcSEcCtD
Pasireotide—SSTR2—GPCR downstream signaling—KNG1—peripheral nervous system neoplasm	0.000957	0.00261	CbGpPWpGaD
Pasireotide—Alopecia—Epirubicin—peripheral nervous system neoplasm	0.000945	0.00178	CcSEcCtD
Pasireotide—SSTR5—Signaling by GPCR—KNG1—peripheral nervous system neoplasm	0.000941	0.00257	CbGpPWpGaD
Pasireotide—Vomiting—Cisplatin—peripheral nervous system neoplasm	0.000941	0.00178	CcSEcCtD
Pasireotide—SSTR5—Signaling Pathways—VIP—peripheral nervous system neoplasm	0.000938	0.00256	CbGpPWpGaD
Pasireotide—SSTR1—Signaling by GPCR—GNAS—peripheral nervous system neoplasm	0.000928	0.00253	CbGpPWpGaD
Pasireotide—Diarrhoea—Etoposide—peripheral nervous system neoplasm	0.000927	0.00175	CcSEcCtD
Pasireotide—SSTR5—GPCR downstream signaling—GNAS—peripheral nervous system neoplasm	0.000906	0.00247	CbGpPWpGaD
Pasireotide—Back pain—Epirubicin—peripheral nervous system neoplasm	0.0009	0.0017	CcSEcCtD
Pasireotide—Dizziness—Etoposide—peripheral nervous system neoplasm	0.000896	0.00169	CcSEcCtD
Pasireotide—Nausea—Cisplatin—peripheral nervous system neoplasm	0.000879	0.00166	CcSEcCtD
Pasireotide—Alopecia—Doxorubicin—peripheral nervous system neoplasm	0.000874	0.00165	CcSEcCtD
Pasireotide—SSTR2—Signaling by GPCR—KNG1—peripheral nervous system neoplasm	0.000869	0.00237	CbGpPWpGaD
Pasireotide—SSTR2—Signaling Pathways—VIP—peripheral nervous system neoplasm	0.000866	0.00236	CbGpPWpGaD
Pasireotide—SSTR5—Signaling Pathways—PPP3R1—peripheral nervous system neoplasm	0.000866	0.00236	CbGpPWpGaD
Pasireotide—Vomiting—Etoposide—peripheral nervous system neoplasm	0.000862	0.00163	CcSEcCtD
Pasireotide—Anaemia—Epirubicin—peripheral nervous system neoplasm	0.00086	0.00162	CcSEcCtD
Pasireotide—Headache—Etoposide—peripheral nervous system neoplasm	0.000849	0.0016	CcSEcCtD
Pasireotide—SSTR2—GPCR downstream signaling—GNAS—peripheral nervous system neoplasm	0.000836	0.00228	CbGpPWpGaD
Pasireotide—Vertigo—Epirubicin—peripheral nervous system neoplasm	0.000836	0.00158	CcSEcCtD
Pasireotide—Back pain—Doxorubicin—peripheral nervous system neoplasm	0.000833	0.00157	CcSEcCtD
Pasireotide—SSTR5—Signaling by GPCR—GNAS—peripheral nervous system neoplasm	0.000823	0.00225	CbGpPWpGaD
Pasireotide—Nausea—Etoposide—peripheral nervous system neoplasm	0.000805	0.00152	CcSEcCtD
Pasireotide—Hypertension—Epirubicin—peripheral nervous system neoplasm	0.000804	0.00152	CcSEcCtD
Pasireotide—SSTR2—Signaling Pathways—PPP3R1—peripheral nervous system neoplasm	0.000799	0.00218	CbGpPWpGaD
Pasireotide—Anaemia—Doxorubicin—peripheral nervous system neoplasm	0.000796	0.0015	CcSEcCtD
Pasireotide—Arthralgia—Epirubicin—peripheral nervous system neoplasm	0.000792	0.0015	CcSEcCtD
Pasireotide—Myalgia—Epirubicin—peripheral nervous system neoplasm	0.000792	0.0015	CcSEcCtD
Pasireotide—Anxiety—Epirubicin—peripheral nervous system neoplasm	0.00079	0.00149	CcSEcCtD
Pasireotide—Vertigo—Doxorubicin—peripheral nervous system neoplasm	0.000774	0.00146	CcSEcCtD
Pasireotide—SSTR3—Signaling Pathways—NTRK2—peripheral nervous system neoplasm	0.000765	0.00209	CbGpPWpGaD
Pasireotide—SSTR2—Signaling by GPCR—GNAS—peripheral nervous system neoplasm	0.00076	0.00207	CbGpPWpGaD
Pasireotide—Hypertension—Doxorubicin—peripheral nervous system neoplasm	0.000744	0.0014	CcSEcCtD
Pasireotide—Myalgia—Doxorubicin—peripheral nervous system neoplasm	0.000733	0.00138	CcSEcCtD
Pasireotide—Arthralgia—Doxorubicin—peripheral nervous system neoplasm	0.000733	0.00138	CcSEcCtD
Pasireotide—SSTR1—Signaling Pathways—NTRK2—peripheral nervous system neoplasm	0.000733	0.002	CbGpPWpGaD
Pasireotide—Anxiety—Doxorubicin—peripheral nervous system neoplasm	0.000731	0.00138	CcSEcCtD
Pasireotide—Hypotension—Epirubicin—peripheral nervous system neoplasm	0.00071	0.00134	CcSEcCtD
Pasireotide—Musculoskeletal discomfort—Epirubicin—peripheral nervous system neoplasm	0.000692	0.00131	CcSEcCtD
Pasireotide—Insomnia—Epirubicin—peripheral nervous system neoplasm	0.000687	0.0013	CcSEcCtD
Pasireotide—SSTR3—Signaling by GPCR—PTPN11—peripheral nervous system neoplasm	0.000673	0.00184	CbGpPWpGaD
Pasireotide—Decreased appetite—Epirubicin—peripheral nervous system neoplasm	0.00066	0.00125	CcSEcCtD
Pasireotide—Hypotension—Doxorubicin—peripheral nervous system neoplasm	0.000657	0.00124	CcSEcCtD
Pasireotide—Fatigue—Epirubicin—peripheral nervous system neoplasm	0.000655	0.00124	CcSEcCtD
Pasireotide—SSTR3—Signaling Pathways—KNG1—peripheral nervous system neoplasm	0.000654	0.00179	CbGpPWpGaD
Pasireotide—SSTR5—Signaling Pathways—NTRK2—peripheral nervous system neoplasm	0.00065	0.00177	CbGpPWpGaD
Pasireotide—Constipation—Epirubicin—peripheral nervous system neoplasm	0.00065	0.00123	CcSEcCtD
Pasireotide—SSTR1—Signaling by GPCR—PTPN11—peripheral nervous system neoplasm	0.000645	0.00176	CbGpPWpGaD
Pasireotide—Musculoskeletal discomfort—Doxorubicin—peripheral nervous system neoplasm	0.00064	0.00121	CcSEcCtD
Pasireotide—Insomnia—Doxorubicin—peripheral nervous system neoplasm	0.000636	0.0012	CcSEcCtD
Pasireotide—SSTR1—Signaling Pathways—KNG1—peripheral nervous system neoplasm	0.000627	0.00171	CbGpPWpGaD
Pasireotide—SSTR3—Signaling Pathways—NTRK1—peripheral nervous system neoplasm	0.000623	0.0017	CbGpPWpGaD
Pasireotide—Gastrointestinal pain—Epirubicin—peripheral nervous system neoplasm	0.000621	0.00117	CcSEcCtD
Pasireotide—Decreased appetite—Doxorubicin—peripheral nervous system neoplasm	0.000611	0.00115	CcSEcCtD
Pasireotide—Fatigue—Doxorubicin—peripheral nervous system neoplasm	0.000606	0.00114	CcSEcCtD
Pasireotide—Constipation—Doxorubicin—peripheral nervous system neoplasm	0.000601	0.00113	CcSEcCtD
Pasireotide—Abdominal pain—Epirubicin—peripheral nervous system neoplasm	0.000601	0.00113	CcSEcCtD
Pasireotide—SSTR2—Signaling Pathways—NTRK2—peripheral nervous system neoplasm	0.0006	0.00164	CbGpPWpGaD
Pasireotide—SSTR1—Signaling Pathways—NTRK1—peripheral nervous system neoplasm	0.000598	0.00163	CbGpPWpGaD
Pasireotide—Gastrointestinal pain—Doxorubicin—peripheral nervous system neoplasm	0.000575	0.00109	CcSEcCtD
Pasireotide—SSTR5—Signaling by GPCR—PTPN11—peripheral nervous system neoplasm	0.000572	0.00156	CbGpPWpGaD
Pasireotide—SSTR3—Signaling Pathways—GNAS—peripheral nervous system neoplasm	0.000572	0.00156	CbGpPWpGaD
Pasireotide—SSTR5—Signaling Pathways—KNG1—peripheral nervous system neoplasm	0.000556	0.00152	CbGpPWpGaD
Pasireotide—Abdominal pain—Doxorubicin—peripheral nervous system neoplasm	0.000556	0.00105	CcSEcCtD
Pasireotide—SSTR1—Signaling Pathways—GNAS—peripheral nervous system neoplasm	0.000548	0.0015	CbGpPWpGaD
Pasireotide—Asthenia—Epirubicin—peripheral nervous system neoplasm	0.000545	0.00103	CcSEcCtD
Pasireotide—Pruritus—Epirubicin—peripheral nervous system neoplasm	0.000537	0.00101	CcSEcCtD
Pasireotide—SSTR5—Signaling Pathways—NTRK1—peripheral nervous system neoplasm	0.00053	0.00145	CbGpPWpGaD
Pasireotide—SSTR2—Signaling by GPCR—PTPN11—peripheral nervous system neoplasm	0.000528	0.00144	CbGpPWpGaD
Pasireotide—Diarrhoea—Epirubicin—peripheral nervous system neoplasm	0.00052	0.000981	CcSEcCtD
Pasireotide—SSTR2—Signaling Pathways—KNG1—peripheral nervous system neoplasm	0.000513	0.0014	CbGpPWpGaD
Pasireotide—Asthenia—Doxorubicin—peripheral nervous system neoplasm	0.000504	0.000952	CcSEcCtD
Pasireotide—Dizziness—Epirubicin—peripheral nervous system neoplasm	0.000502	0.000948	CcSEcCtD
Pasireotide—Pruritus—Doxorubicin—peripheral nervous system neoplasm	0.000497	0.000939	CcSEcCtD
Pasireotide—SSTR2—Signaling Pathways—NTRK1—peripheral nervous system neoplasm	0.000489	0.00134	CbGpPWpGaD
Pasireotide—SSTR5—Signaling Pathways—GNAS—peripheral nervous system neoplasm	0.000486	0.00133	CbGpPWpGaD
Pasireotide—Vomiting—Epirubicin—peripheral nervous system neoplasm	0.000483	0.000912	CcSEcCtD
Pasireotide—Diarrhoea—Doxorubicin—peripheral nervous system neoplasm	0.000481	0.000908	CcSEcCtD
Pasireotide—Headache—Epirubicin—peripheral nervous system neoplasm	0.000476	0.000898	CcSEcCtD
Pasireotide—Dizziness—Doxorubicin—peripheral nervous system neoplasm	0.000465	0.000877	CcSEcCtD
Pasireotide—Nausea—Epirubicin—peripheral nervous system neoplasm	0.000451	0.000852	CcSEcCtD
Pasireotide—SSTR2—Signaling Pathways—GNAS—peripheral nervous system neoplasm	0.000449	0.00123	CbGpPWpGaD
Pasireotide—Vomiting—Doxorubicin—peripheral nervous system neoplasm	0.000447	0.000844	CcSEcCtD
Pasireotide—Headache—Doxorubicin—peripheral nervous system neoplasm	0.00044	0.000831	CcSEcCtD
Pasireotide—Nausea—Doxorubicin—peripheral nervous system neoplasm	0.000418	0.000788	CcSEcCtD
Pasireotide—SSTR3—Signaling by GPCR—NRAS—peripheral nervous system neoplasm	0.000404	0.0011	CbGpPWpGaD
Pasireotide—SSTR3—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	0.000397	0.00109	CbGpPWpGaD
Pasireotide—SSTR1—Signaling by GPCR—NRAS—peripheral nervous system neoplasm	0.000388	0.00106	CbGpPWpGaD
Pasireotide—SSTR1—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	0.000381	0.00104	CbGpPWpGaD
Pasireotide—SSTR5—Signaling by GPCR—NRAS—peripheral nervous system neoplasm	0.000344	0.000939	CbGpPWpGaD
Pasireotide—SSTR5—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	0.000338	0.000923	CbGpPWpGaD
Pasireotide—SSTR2—Signaling by GPCR—NRAS—peripheral nervous system neoplasm	0.000317	0.000867	CbGpPWpGaD
Pasireotide—SSTR3—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	0.000314	0.000858	CbGpPWpGaD
Pasireotide—SSTR2—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	0.000312	0.000851	CbGpPWpGaD
Pasireotide—SSTR1—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	0.000301	0.000822	CbGpPWpGaD
Pasireotide—SSTR3—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	0.000296	0.000808	CbGpPWpGaD
Pasireotide—SSTR3—GPCR downstream signaling—AKT1—peripheral nervous system neoplasm	0.000288	0.000786	CbGpPWpGaD
Pasireotide—SSTR3—Signaling Pathways—CASP3—peripheral nervous system neoplasm	0.000285	0.000778	CbGpPWpGaD
Pasireotide—SSTR1—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	0.000284	0.000775	CbGpPWpGaD
Pasireotide—SSTR1—GPCR downstream signaling—AKT1—peripheral nervous system neoplasm	0.000276	0.000753	CbGpPWpGaD
Pasireotide—SSTR1—Signaling Pathways—CASP3—peripheral nervous system neoplasm	0.000273	0.000746	CbGpPWpGaD
Pasireotide—SSTR5—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	0.000267	0.000729	CbGpPWpGaD
Pasireotide—SSTR3—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	0.000261	0.000713	CbGpPWpGaD
Pasireotide—SSTR5—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	0.000252	0.000687	CbGpPWpGaD
Pasireotide—SSTR1—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	0.000251	0.000684	CbGpPWpGaD
Pasireotide—SSTR2—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	0.000246	0.000673	CbGpPWpGaD
Pasireotide—SSTR5—GPCR downstream signaling—AKT1—peripheral nervous system neoplasm	0.000245	0.000668	CbGpPWpGaD
Pasireotide—SSTR5—Signaling Pathways—CASP3—peripheral nervous system neoplasm	0.000242	0.000662	CbGpPWpGaD
Pasireotide—SSTR3—Signaling Pathways—NRAS—peripheral nervous system neoplasm	0.000239	0.000652	CbGpPWpGaD
Pasireotide—SSTR2—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	0.000232	0.000634	CbGpPWpGaD
Pasireotide—SSTR1—Signaling Pathways—NRAS—peripheral nervous system neoplasm	0.000229	0.000626	CbGpPWpGaD
Pasireotide—SSTR2—GPCR downstream signaling—AKT1—peripheral nervous system neoplasm	0.000226	0.000616	CbGpPWpGaD
Pasireotide—SSTR2—Signaling Pathways—CASP3—peripheral nervous system neoplasm	0.000224	0.000611	CbGpPWpGaD
Pasireotide—SSTR3—Signaling Pathways—MYC—peripheral nervous system neoplasm	0.000223	0.000608	CbGpPWpGaD
Pasireotide—SSTR5—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	0.000222	0.000607	CbGpPWpGaD
Pasireotide—SSTR1—Signaling Pathways—MYC—peripheral nervous system neoplasm	0.000213	0.000583	CbGpPWpGaD
Pasireotide—SSTR2—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	0.000205	0.00056	CbGpPWpGaD
Pasireotide—SSTR5—Signaling Pathways—NRAS—peripheral nervous system neoplasm	0.000203	0.000555	CbGpPWpGaD
Pasireotide—SSTR5—Signaling Pathways—MYC—peripheral nervous system neoplasm	0.000189	0.000517	CbGpPWpGaD
Pasireotide—SSTR2—Signaling Pathways—NRAS—peripheral nervous system neoplasm	0.000188	0.000512	CbGpPWpGaD
Pasireotide—SSTR3—Signaling Pathways—TP53—peripheral nervous system neoplasm	0.000183	0.000499	CbGpPWpGaD
Pasireotide—SSTR1—Signaling Pathways—TP53—peripheral nervous system neoplasm	0.000175	0.000478	CbGpPWpGaD
Pasireotide—SSTR3—Signaling Pathways—HRAS—peripheral nervous system neoplasm	0.000175	0.000477	CbGpPWpGaD
Pasireotide—SSTR2—Signaling Pathways—MYC—peripheral nervous system neoplasm	0.000175	0.000477	CbGpPWpGaD
Pasireotide—SSTR1—Signaling Pathways—HRAS—peripheral nervous system neoplasm	0.000168	0.000458	CbGpPWpGaD
Pasireotide—SSTR5—Signaling Pathways—TP53—peripheral nervous system neoplasm	0.000155	0.000424	CbGpPWpGaD
Pasireotide—SSTR3—Signaling Pathways—AKT1—peripheral nervous system neoplasm	0.000154	0.000421	CbGpPWpGaD
Pasireotide—SSTR5—Signaling Pathways—HRAS—peripheral nervous system neoplasm	0.000149	0.000406	CbGpPWpGaD
Pasireotide—SSTR1—Signaling Pathways—AKT1—peripheral nervous system neoplasm	0.000148	0.000404	CbGpPWpGaD
Pasireotide—SSTR2—Signaling Pathways—TP53—peripheral nervous system neoplasm	0.000143	0.000392	CbGpPWpGaD
Pasireotide—SSTR2—Signaling Pathways—HRAS—peripheral nervous system neoplasm	0.000137	0.000375	CbGpPWpGaD
Pasireotide—SSTR5—Signaling Pathways—AKT1—peripheral nervous system neoplasm	0.000131	0.000358	CbGpPWpGaD
Pasireotide—SSTR2—Signaling Pathways—AKT1—peripheral nervous system neoplasm	0.000121	0.000331	CbGpPWpGaD
